Current status of pharmaceutical and genetic therapeutic approaches to treat DMD
Duchenne muscular dystrophy (DMD) is a genetic disease affecting about one in every 3,500 boys. This X-linked pathology is due to the absence of dystrophin in muscle fibers. This lack of dystrophin leads to the progressive muscle degeneration that is often responsible for the death of the DMD patien...
主要な著者: | Pichavant, C, Aartsma-Rus, A, Clemens, P, Davies, K, Dickson, G, Takeda, S, Wilton, S, Wolff, J, Wooddell, C, Xiao, X, Tremblay, J |
---|---|
フォーマット: | Journal article |
言語: | English |
出版事項: |
2011
|
類似資料
-
Current status of pharmaceutical and genetic therapeutic approaches to treat DMD.
著者:: Pichavant, C, 等
出版事項: (2011) -
Utrophin upregulation in DMD therapy: current status and new tools for the future
著者:: Fairclough, R, 等
出版事項: (2011) -
DMD antisense oligonucleotide mediated exon skipping efficiency correlates with flanking intron retention time and target position within the exon
著者:: Remko Goossens, 等
出版事項: (2023-12-01) -
BMP antagonists enhance myogenic differentiation and ameliorate the dystrophic phenotype in a DMD mouse model
著者:: SongTing Shi, 等
出版事項: (2011-02-01) -
DMD and West syndrome
著者:: Cardas, R, 等
出版事項: (2017)